Bristol-Myers Squibb Pharmaceutical Limited

Bristol-Myers Squibb House, Uxbridge Business Park, Sanderson Road, Uxbridge, Middlesex, UB8 1DH , UK
Telephone: +44 (0)1895 523 000
Fax: +44 (0)1895 523 010
Medical Information Direct Line: +44 (0)1895 523 740
Medical Information e-mail: medical.information@bms.com
Medical Information Fax: +44 (0)1895 523 677

Patient Information Leaflet last updated on the eMC: 12/07/2010
PIL ORENCIA 250 mg powder for concentrate for solution for infusion

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 12/07/2010 and displayed until Current
Reasons for adding or updating:
  • Change to how the medicine works
  • Change to date of revision
  • Change to side-effects
Updated on 02/02/2010 and displayed until 12/07/2010
Reasons for adding or updating:
  • Change to date of revision
  • Change to, or new, use for medicine
  • Change to side-effects
  • Changes to therapeutic indications
Updated on 03/07/2009 and displayed until 02/02/2010
Reasons for adding or updating:
  • Change to Further Information section
  • Change to date of revision
Updated on 03/07/2007 and displayed until 03/07/2009
Reasons for adding or updating:
  • Improved Electronic Presentation
Updated on 08/06/2007 and displayed until 03/07/2007
Reasons for adding or updating:
  • New PIL for new product

Active Ingredients/Generics

 
   abatacept